Drugmaker Cipla has got regulatory approval to market Afrezza, a rapid acting insulin delivered through an inhaler, as compared to other insulins given through injections. The Central Drugs ...

Cipla secures CDSCO approval for Afrezza, a rapid-acting insulin delivered through an inhaler, offering a convenient solution for diabetes management in India. The drug is the first and only ...

Drugmaker Cipla has got regulatory approval to market Afrezza, a rapid acting insulin delivered through an inhaler, as compared to other insulins given through injections. The Central Drugs ...

Expert Rev Pharmacoeconomics Outcomes Res. 2008;8(1):33-42. Human inhaled insulin powder (HIIP) is a dry-powder inhaled insulin product, in which regular insulin is captured in large porous ...

Cipla Limited on Wednesday announced that it has obtained regulatory approval from Central Drugs Standard Control Organisation (CDSCO) for the exclusive distribution and marketing of Afrezza ...

Mumbai, Dec 11 Indian regulator Central Drugs Standard Control Organisation (CDSCO) has approved Cipla to exclusively distribute and market inhaled insulin in the country, the drugmaker said on ...

MUMBAI:Indian regulator Central Drugs Standard Control Organisation (CDSCO) has approved Cipla to exclusively distribute and market inhaled insulin in the country, the drugmaker said on Wednesday. The ...

announced today that the Central Drugs Standard Control Organisation (CDSCO) in India has approved Afrezza (insulin human) Inhalation Powder in adults. The CDSCO decision follows existing ...

Several inhaled insulin products are under development. If these products receive marketing approval, the pulmonary delivery of insulin may offer patients with diabetes an alternative to repeated ...